FOLD
AMICUS THERAPEUTICS, INC.Company Information
- Company Name
- AMICUS THERAPEUTICS, INC.
- CIK
- CIK0001178879
- Category
- Large accelerated filer
- Ticker: Exchange
- FOLD: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- FOLD
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-03-02
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 406,950
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 308,944,394
- Shares outstanding
- 308,363,768
- Ownership
- 100.19%
Earnings Market Reaction
- Filing date
- 2026-02-20
- Price on filing date
- —
- 1-month reaction
- 0.21%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 214 | 191 | 159 | 182 | 214 | 234 | 209 | 210 | 247 | 263 | 211 | 161 | ||||||
| Marketable Securities Current | 80 | 73 | 72 | 69 | 36 | 16 | 51 | 30 | 39 | 17 | 54 | 107 | ||||||
| Accounts Receivable Net Current | 115 | 114 | 106 | 88 | 101 | 98 | 85 | 76 | 88 | 73 | 64 | 68 | ||||||
| Inventory Net | 229 | 178 | 155 | 132 | 119 | 115 | 81 | 61 | 60 | 57 | 51 | 27 | ||||||
| Prepaid Expense And Other Assets Current | 39 | 38 | 46 | 39 | 35 | 35 | 35 | 54 | 50 | 53 | 52 | 37 | ||||||
| Assets Current | 676 | 594 | 538 | 511 | 505 | 498 | 462 | 431 | 483 | 463 | 433 | 400 | ||||||
| Operating Lease Right Of Use Asset | 21 | 22 | 22 | 22 | 22 | 23 | 23 | 23 | 26 | 30 | 28 | 28 | ||||||
| Property Plant And Equipment Net | 27 | 28 | 29 | 29 | 29 | 30 | 31 | 32 | 32 | 31 | 30 | 31 | ||||||
| Intangible Assets Net Excluding Goodwill | 14 | 15 | 16 | 16 | 17 | 18 | 19 | 20 | 20 | 21 | 22 | 23 | ||||||
| Goodwill | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 | ||||||
| Other Assets Noncurrent | 14 | 13 | 13 | 14 | 14 | 19 | 17 | 18 | 19 | 21 | 19 | 20 | ||||||
| Assets | 950 | 869 | 815 | 790 | 785 | 787 | 749 | 722 | 778 | 764 | 730 | 701 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 29 | 19 | 14 | 14 | 13 | 13 | 32 | 9 | 15 | 23 | 14 | 25 | ||||||
| Accrued Liabilities And Other Liabilities | 200 | 171 | 145 | 130 | 127 | 136 | 128 | 125 | 144 | 139 | 125 | 93 | ||||||
| Business Combination Contingent Consideration Liability Current | - | - | - | - | - | - | - | - | 0 | 0 | 13 | 13 | ||||||
| Operating Lease Liability Current | 9 | 9 | 9 | 9 | 8 | 9 | 8 | 8 | 8 | 8 | 8 | 8 | ||||||
| Liabilities Current | 238 | 199 | 168 | 153 | 149 | 158 | 168 | 142 | 168 | 169 | 159 | 138 | ||||||
| Long Term Debt | 393 | 392 | 391 | 391 | 390 | 389 | 389 | 388 | 388 | 394 | 393 | 393 | ||||||
| Operating Lease Liability Noncurrent | 41 | 42 | 43 | 44 | 45 | 47 | 47 | 48 | 49 | 52 | 51 | 51 | ||||||
| Deferred Credits And Other Liabilities Noncurrent | - | - | - | - | - | - | - | - | - | 6 | 6 | 6 | ||||||
| Deferred Income Tax Liabilities Net | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Other Liabilities Noncurrent | 4 | 5 | 9 | 8 | 7 | 13 | 13 | 13 | 13 | 9 | 9 | 10 | ||||||
| Liabilities | 676 | 638 | 611 | 596 | 591 | 608 | 617 | 591 | 618 | 631 | 619 | 598 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Treasury Stock Common Value | -0 | -0 | -0 | -0 | 0 | - | - | - | - | - | - | - | ||||||
| Additional Paid In Capital Common Stock | 3,014 | 2,974 | 2,957 | 2,940 | 2,926 | 2,906 | 2,869 | 2,854 | 2,836 | 2,787 | 2,733 | 2,692 | ||||||
Accumulated Other Comprehensive Income Loss Net Of Tax | ||||||||||||||||||
| Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax | 24 | 23 | 31 | 13 | 5 | 25 | 9 | 7 | 5 | -7 | 4 | -7 | ||||||
| Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Warrants And Rights Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -2,767 | -2,769 | -2,786 | -2,762 | -2,740 | -2,755 | -2,748 | -2,732 | -2,684 | -2,650 | -2,629 | -2,585 | ||||||
| Stockholders Equity | 274 | 230 | 204 | 194 | 194 | 179 | 133 | 131 | 160 | 133 | 112 | 103 | ||||||
| Liabilities And Stockholders Equity | 950 | 869 | 815 | 790 | 785 | 787 | 749 | 722 | 778 | 764 | 730 | 701 | ||||||
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | 32 | 31 | 31 | 30 | 29 | 29 | 28 | 27 | 25 | 25 | 24 | 23 | ||||||
| Finite Lived Intangible Assets Accumulated Amortization | 9 | 8 | 7 | 7 | 6 | 5 | 4 | 3 | 3 | 2 | 1 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 311 | 308 | 308 | 308 | 299 | 299 | 296 | 296 | 294 | 291 | 287 | 283 | ||||||
| Shares Outstanding | 311 | 308 | 308 | 308 | 299 | 299 | 296 | 296 | 294 | 291 | 287 | 283 | ||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAMICUS THERAPEUTICS, INC. (FOLD) — SEC Financial Statements & Analysis
AMICUS THERAPEUTICS, INC. (FOLD) is a pharmaceutical preparations company, incorporated in DE. AMICUS THERAPEUTICS, INC. trades on Nasdaq as: FOLD. AMICUS THERAPEUTICS, INC. (FOLD)'s most recent SEC filing is a Form 10-K for the period ended 2025-12-31, filed with the SEC on 2026-02-20. Based on its latest SEC filing (Form 10-Q, period ending 2025-12-31), On profitability, AMICUS THERAPEUTICS, INC. posts a gross margin of 88.50%, an operating margin of 5.17%, a net margin of -4.27%, a Return on Equity (ROE) of -11.58%, a Return on Assets (ROA) of -3.13%, and a Return on Invested Capital (ROIC) of 0.00%. Per share, it reports EPS of $-0.09, diluted EPS of $-0.09, free cash flow per share of $0.10, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 20.05% year-over-year, net income growth of -51.68% year-over-year, and EPS growth of -52.30% year-over-year. On the balance sheet, it maintains a current ratio of 2.84x, a quick ratio of 1.72x, working capital of $438.35M, a debt-to-equity ratio of 2.46x, a debt ratio of 0.71, an interest coverage ratio of 0.71x, free cash flow of $29.85M (TTM), and net debt of $175.34M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-0.09
- ROE TTM
- -11.58%
- ROA TTM
- -3.13%
- Debt To Equity
- 2.46x
- Free Cash Flow TTM
- $29.85M
- Net Revenue TTM Growth 1Y
- 20.05%
Data as of 2025-12-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is AMICUS THERAPEUTICS, INC. in?
AMICUS THERAPEUTICS, INC. (FOLD) operates in the Pharmaceutical Preparations industry.
What exchange does FOLD trade on?
AMICUS THERAPEUTICS, INC. (FOLD) trades on the Nasdaq.
Where is AMICUS THERAPEUTICS, INC. incorporated?
AMICUS THERAPEUTICS, INC. is incorporated in DE.
When was AMICUS THERAPEUTICS, INC. (FOLD)'s most recent SEC filing?
AMICUS THERAPEUTICS, INC. (FOLD)'s most recent SEC filing is a Form 10-K for the period ended 2025-12-31, filed with the SEC on 2026-02-20.
What is FOLD's EPS (earnings per share)?
AMICUS THERAPEUTICS, INC. (FOLD)'s trailing twelve month EPS is $-0.09 as of 2025-12-31.
What is FOLD's ROE (return on equity)?
AMICUS THERAPEUTICS, INC. (FOLD)'s trailing twelve month Return on Equity (ROE) is -11.58% as of 2025-12-31.
What is FOLD's ROA (return on assets)?
AMICUS THERAPEUTICS, INC. (FOLD)'s trailing twelve month Return on Assets (ROA) is -3.13% as of 2025-12-31.
What is FOLD's ROIC (return on invested capital)?
AMICUS THERAPEUTICS, INC. (FOLD)'s trailing twelve month Return on Invested Capital (ROIC) is 0.00% as of 2025-12-31.